The experience of every cancer patient is a powerful legacy. Each patient’s story has the unique potential to teach us something new about the way cancer works, and help us find more effective treatments, faster.
At Flatiron, we believe that learning from the experience of every cancer patient is an imperative — it is the key to accelerating research and continuing to improve the quality of care. What stands in the way is an overwhelming technology challenge: Much of the available, real-world clinical data is unstructured and stored across thousands of disconnected community clinics, medical centers and hospitals. It is a problem that we believe we can solve.
Flatiron Health has come a long way since 2012, when entrepreneurs Nat Turner and Zach Weinberg saw firsthand how a fragmented and siloed healthcare system impacted a family member’s cancer treatment, and set out to gather the best minds in medicine and technology to transform the way cancer is understood and treated. Today, Flatiron continues to lead in U.S. oncology real-world data; partners with hundreds of cancer centers and the world’s top developers of oncology therapeutics, and collaborates with researchers and regulators to accelerate R&D and impact treatment for patients worldwide. In 2018, Flatiron became an independent affiliate of the Roche Group. In April 2021, Nat and Zach stepped down from Flatiron management and Carolyn Starrett succeeded Nat as CEO. Nat remains Chair of Flatiron’s Board of Directors.
2.5 million active patient records available for research by Flatiron's solutions
Over 15 of the top therapeutic oncology companies work with Flatiron
280+ community oncology practices
2,600+ OncoEMR® clinician users
Flatiron's OCM network includes 55 community oncology practices across 20 states
Seven major academic research centers partner with Flatiron
Headquarters in NYC, office in SF